News
5h
ScienceAlert on MSNNew Weight Loss Drug Outperformed Existing Treatment in Clinical Trial
Under brand names like Ozempic and Wegovy, semaglutide-based medications have made a significant difference in treating type ...
Dentists claim weight-loss drugs could majorly impact users' saliva glands, helping gum disease to fester in their mouths.
“Most users tolerate GLP-1 medications like Ozempic without serious oral health issues, but a subset experience notable side ...
Participants on the 36 mg oral dose drop 12.4% of their body weight at 72 weeks, yet physicians warn of posttreatment weight ...
GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...
The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...
Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...
Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...
6d
MedPage Today on MSNSemaglutide Gets FDA Greenlight for MASH
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
19d
Pharmaceutical Technology on MSNNovo Nordisk files 14 new lawsuits against unapproved semaglutide drugs
Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain ...
Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results